ACIU – ac immune sa (US:NASDAQ)

DELAYED

<$


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

1D

5D

1M

3M

YTD

1Y

3Y

1 Day —— ACIU SPY QQQ SPX

Date

Time

Symbol

Headline

Impact

AC Immune SA (NASDAQ: ACIU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.

AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating.

AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.

AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating.

AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating.

AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating.

The most promising breakthrough in Alzheimer’s treatment is not a drug [Yahoo! Finance News]

AC Immune to Present at Jefferies 2019 London Healthcare Conference

AC Immune Q3 2019 Financial Results and Business Update

AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.

AC Immune Hosts Key Opinion Leader Event: ‘Untangling’ Tau Pathology to Treat Alzheimer’s and Neurodegenerative Diseases

AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating.

AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.

AC Immune to Host Key Opinion Leader Event: ‘Untangling’ Tau Pathology to Treat Alzheimer’s and Neurodegenerative Diseases

Advocate Health Care is enrolling adults with Down syndrome for the first research study in the Down Syndrome Clinical Trials Network Supported by LuMind IDSC Foundation

Massachusetts General Hospital First to Enroll Adults with Down Syndrome in New Nation-Wide Research Study Supported by LuMind IDSC Foundation

AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.50 price target on the stock.

Life Molecular Imaging and Positron Pharma announce a strategic partnership for manufacturing and distribution of PI-2620 in Chile

Life Molecular Imaging announces presentation of new research results at the European Association of Nuclear Medicine 2019 Annual Meeting

AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating.

AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.

AC Immune earns CHF30M milestone from Eli Lilly [Seeking Alpha]

AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer™ Program

AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial of Tau PET Tracer PI-2620

Life Molecular Imaging started recruitment for longitudinal Phase 2 study with the Tau tracer PI-2620

Live Event:

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day